Zhihui Yue
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zhihui Yue has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Liangzhong Sun
Department of Pediatrics, Nanfang Hospital, Southern Medical University, Guangzhou, China
4 shared publications Huamu Chen
Department of Pediatrics, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China
3 shared publicationsXiaoya Wei
Department of Pediatrics, Daping hospital, Army Medical University, Chongqing, 400042, China
3 shared publicationsDantong Li
Department of Nephrology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, China
2 shared publicationsHongrong Lin
Department of Pediatrics, Nanfang Hospital, Southern Medical University, Guangzhou, China
2 shared publications- Jiayong Lai
Department of Pediatrics, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China
2 shared publications
Latest Publications
- Open Access
- 8 July 2026
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 14, 1874241
Effect of nusinersen on respiratory function in patients with spinal muscular atrophy: an 18-month single-center prospective study
Background: Spinal muscular atrophy (SMA) is a severe neuromuscular disease characterized by respiratory muscle weakness, often leading to high mortality. Research on the effect of nusinersen on respiratory function in SMA patients remains scarce. Objective: To evaluate nusinersen's effect on respiratory function in SMA patients and provide a clinical basis for respiratory management. Methods: In this single-center prospective study, clinical data were collected from SMA patients in our pediatric department. Respiratory function, expressed as absolute values and percentages of predicted values (%pred), and active cough strength was evaluated at baseline and during follow-up after nusinersen treatment. Treatment effects were subsequently analyzed. Results: Among 59 SMA patients (39 Type II; 20 Type III), 40 completed baseline respiratory tests, of whom 67.5% had abnormal respiratory function. Type II patients had significantly lower VC %pred, FVC %pred, FEV1%pred, PEF %pred, FEF25%pred, and FEF50%pred than Type III patients (all P < 0.05). After 6 months, absolute value of FVC improved significantly in Type III ( P < 0.05); by 18 months, absolute VC values in Type II patients, and absolute values and %pred of VC, FVC, FEF25, FEF50, and FEF75 in Type III increased significantly (all P < 0.05). Ineffective cough was observed in 76.3% of patients at baseline, and was more common in Type II patients ( P = 0.001). Among patients who completed 18-month respiratory function follow-up ( n = 23), the proportion with effective cough increased significantly from 39.1% (9/23) at baseline to 56.5% (13/23) after treatment ( P < 0.05). Conclusion: Most SMA patients had impaired respiratory function, which was more severe in Type II than Type III patients. Nusinersen improved respiratory function and active cough strength, but could not fully reverse the progression of restrictive ventilatory dysfunction, especially in Type II.
- 8 July 2026
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 14, 1874241
Open AccessEffect of nusinersen on respiratory function in patients with spinal muscular atrophy: an 18-month single-center prospective study
Background: Spinal muscular atrophy (SMA) is a severe neuromuscular disease characterized by respiratory muscle weakness, often leading to high mortality. Research on the effect of nusinersen on respiratory function in SMA patients remains scarce. Objective: To evaluate nusinersen's effect on respiratory function in SMA patients and provide a clinical basis for respiratory management. Methods: In this single-center prospective study, clinical data were collected from SMA patients in our pediatric department. Respiratory function, expressed as absolute values and percentages of predicted values (%pred), and active cough strength was evaluated at baseline and during follow-up after nusinersen treatment. Treatment effects were subsequently analyzed. Results: Among 59 SMA patients (39 Type II; 20 Type III), 40 completed baseline respiratory tests, of whom 67.5% had abnormal respiratory function. Type II patients had significantly lower VC %pred, FVC %pred, FEV1%pred, PEF %pred, FEF25%pred, and FEF50%pred than Type III patients (all P < 0.05). After 6 months, absolute value of FVC improved significantly in Type III ( P < 0.05); by 18 months, absolute VC values in Type II patients, and absolute values and %pred of VC, FVC, FEF25, FEF50, and FEF75 in Type III increased significantly (all P < 0.05). Ineffective cough was observed in 76.3% of patients at baseline, and was more common in Type II patients ( P = 0.001). Among patients who completed 18-month respiratory function follow-up ( n = 23), the proportion with effective cough increased significantly from 39.1% (9/23) at baseline to 56.5% (13/23) after treatment ( P < 0.05). Conclusion: Most SMA patients had impaired respiratory function, which was more severe in Type II than Type III patients. Nusinersen improved respiratory function and active cough strength, but could not fully reverse the progression of restrictive ventilatory dysfunction, especially in Type II.
- 6 December 2025
- Published by Elsevier in Translational Research
- Vol. 285-286, 48-58
ZONAB regulates renal cyst formation in nphp1 knockout mice
- 6 December 2025
- Published by Elsevier in Translational Research
- Vol. 285-286, 48-58
ZONAB regulates renal cyst formation in nphp1 knockout mice
- Open Access
- 7 April 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1521763
Case Report: Maribavir for refractory cytomegalovirus viremia after renal transplantation in a child with Schimke’s immune-osseous dysplasia
Cytomegalovirus (CMV) is a major opportunistic pathogen in recipients of solid organ transplantation. Maribavir, a pUL97 protein kinase inhibitor, was approved for the treatment of refractory post-transplant CMV infection in the US in 2021. However, it is rarely used in pediatric patients worldwide. Here, we report the case of a Chinese boy with Schimke’s immune-osseous dysplasia (SIOD) who developed refractory CMV infection after a renal transplantation. An 11-year-old boy was hospitalized with recurrent abdominal and testicular pain 50 days after renal transplantation. Diagnoses included urinary tract infection, epididymitis, CMV viremia, stage 2 chronic kidney disease, and SIOD. After five days of treatment, his pain improved, but he developed persistent fever and shortness of breath. Blood CMV levels rose to 1.64 × 105 copies/ml after one month of ganciclovir treatment. Significant bone marrow suppression was observed after combined treatment with foscarnet. Anti-rejection treatment was discontinued due to compromised immune function. On day 40, maribavir was initiated with parental consent, resulting in undetectable CMV copies within four days. The patient’s clinical status and bone marrow suppression had improved. Continuing maribavir for two weeks led to the disappearance of CMV viremia, no bone marrow suppression, and normal liver and kidney functions. This case demonstrates the successful short-term use of maribavir in the treatment of refractory CMV infection in an immune-deficient child after renal transplantation. Further studies are required to explore the efficacy and safety of maribavir in pediatric patients.
- 7 April 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1521763
Open AccessCase Report: Maribavir for refractory cytomegalovirus viremia after renal transplantation in a child with Schimke’s immune-osseous dysplasia
Cytomegalovirus (CMV) is a major opportunistic pathogen in recipients of solid organ transplantation. Maribavir, a pUL97 protein kinase inhibitor, was approved for the treatment of refractory post-transplant CMV infection in the US in 2021. However, it is rarely used in pediatric patients worldwide. Here, we report the case of a Chinese boy with Schimke’s immune-osseous dysplasia (SIOD) who developed refractory CMV infection after a renal transplantation. An 11-year-old boy was hospitalized with recurrent abdominal and testicular pain 50 days after renal transplantation. Diagnoses included urinary tract infection, epididymitis, CMV viremia, stage 2 chronic kidney disease, and SIOD. After five days of treatment, his pain improved, but he developed persistent fever and shortness of breath. Blood CMV levels rose to 1.64 × 105 copies/ml after one month of ganciclovir treatment. Significant bone marrow suppression was observed after combined treatment with foscarnet. Anti-rejection treatment was discontinued due to compromised immune function. On day 40, maribavir was initiated with parental consent, resulting in undetectable CMV copies within four days. The patient’s clinical status and bone marrow suppression had improved. Continuing maribavir for two weeks led to the disappearance of CMV viremia, no bone marrow suppression, and normal liver and kidney functions. This case demonstrates the successful short-term use of maribavir in the treatment of refractory CMV infection in an immune-deficient child after renal transplantation. Further studies are required to explore the efficacy and safety of maribavir in pediatric patients.
- Open Access
- 31 July 2023
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 11, 1192935
Identification of renal cyst cells of type I Nephronophthisis by single-nucleus RNA sequencing
Background: Nephronophthisis (NPH) is the most common genetic cause of end-stage renal disease (ESRD) in childhood, and NPHP1 is the major pathogenic gene. Cyst formation at the corticomedullary junction is a pathological feature of NPH, but the mechanism underlying cystogenesis is not well understood. The isolation and identification of cystic cell subpopulation could help to identify their origins and provide vital clues to the mechanisms underlying cystogenesis in NPH.Methods: Single-nucleus RNA sequencing (snRNA-seq) was performed to produce an atlas of NPHP1 renal cells. Kidney samples were collected from WT (Nphp1+/+) mice and NPHP1 (Nphp1del2-20/del2-20) model mice.Results: A comprehensive atlas of the renal cellular landscape in NPHP1 was generated, consisting of 14 basic renal cell types as well as a subpopulation of DCT cells that was overrepresented in NPHP1 kidneys compared to WT kidneys. GO analysis revealed significant downregulation of genes associated with tubular development and kidney morphogenesis in this subpopulation. Furthermore, the reconstruction of differentiation trajectories of individual cells within this subpopulation confirmed that a specific group of cells in NPHP1 mice become arrested at an early stage of differentiation and proliferate to form cysts. We demonstrate that Niban1 is a specific molecular marker of cystic cells in both mice and human NPHP1.Conclusion: In summary, we report a novel subpopulation of DCT cells, marked by Niban1, that are classified as cystic cells in the NPHP1 mice kidney. These results offer fresh insights into the cellular and molecular basis of cystogenesis in NPH.
- 31 July 2023
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 11, 1192935
Open AccessIdentification of renal cyst cells of type I Nephronophthisis by single-nucleus RNA sequencing
Background: Nephronophthisis (NPH) is the most common genetic cause of end-stage renal disease (ESRD) in childhood, and NPHP1 is the major pathogenic gene. Cyst formation at the corticomedullary junction is a pathological feature of NPH, but the mechanism underlying cystogenesis is not well understood. The isolation and identification of cystic cell subpopulation could help to identify their origins and provide vital clues to the mechanisms underlying cystogenesis in NPH.Methods: Single-nucleus RNA sequencing (snRNA-seq) was performed to produce an atlas of NPHP1 renal cells. Kidney samples were collected from WT (Nphp1+/+) mice and NPHP1 (Nphp1del2-20/del2-20) model mice.Results: A comprehensive atlas of the renal cellular landscape in NPHP1 was generated, consisting of 14 basic renal cell types as well as a subpopulation of DCT cells that was overrepresented in NPHP1 kidneys compared to WT kidneys. GO analysis revealed significant downregulation of genes associated with tubular development and kidney morphogenesis in this subpopulation. Furthermore, the reconstruction of differentiation trajectories of individual cells within this subpopulation confirmed that a specific group of cells in NPHP1 mice become arrested at an early stage of differentiation and proliferate to form cysts. We demonstrate that Niban1 is a specific molecular marker of cystic cells in both mice and human NPHP1.Conclusion: In summary, we report a novel subpopulation of DCT cells, marked by Niban1, that are classified as cystic cells in the NPHP1 mice kidney. These results offer fresh insights into the cellular and molecular basis of cystogenesis in NPH.
- Open Access
- 9 February 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (4) , 3504
Reducing GEF-H1 Expression Inhibits Renal Cyst Formation, Inflammation, and Fibrosis via RhoA Signaling in Nephronophthisis
Nephronophthisis (NPHP) is the most prevalent monogenic disease leading to end-stage renal failure in childhood. RhoA activation is involved in NPHP pathogenesis. This study explored the role of the RhoA activator guanine nucleotide exchange factor (GEF)-H1 in NPHP pathogenesis. We analyzed the expression and distribution of GEF-H1 in NPHP1 knockout (NPHP1KO) mice using Western blotting and immunofluorescence, followed by GEF-H1 knockdown. Immunofluorescence and renal histology were used to examine the cysts, inflammation, and fibrosis. A RhoA GTPase activation assay and Western blotting were used to detect the expression of downstream GTP-RhoA and p-MLC2, respectively. In NPHP1 knockdown (NPHP1KD) human kidney proximal tubular cells (HK2 cells), we detected the expressions of E-cadherin and α-smooth muscle actin (α-SMA). In vivo, increased expression and redistribution of GEF-H1, and higher levels of GTP-RhoA and p-MLC2 in renal tissue of NPHP1KO mice were observed, together with renal cysts, fibrosis, and inflammation. These changes were alleviated by GEF-H1 knockdown. In vitro, the expression of GEF-H1 and activation of RhoA were also increased, with increased expression of α-SMA and decreased E-cadherin. GEF-H1 knockdown reversed these changes in NPHP1KD HK2 cells. Thus, the GEF-H1/RhoA/MLC2 axis is activated in NPHP1 defects and may play a pivotal role in NPHP pathogenesis.
- 9 February 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (4) , 3504
Open AccessReducing GEF-H1 Expression Inhibits Renal Cyst Formation, Inflammation, and Fibrosis via RhoA Signaling in Nephronophthisis
Nephronophthisis (NPHP) is the most prevalent monogenic disease leading to end-stage renal failure in childhood. RhoA activation is involved in NPHP pathogenesis. This study explored the role of the RhoA activator guanine nucleotide exchange factor (GEF)-H1 in NPHP pathogenesis. We analyzed the expression and distribution of GEF-H1 in NPHP1 knockout (NPHP1KO) mice using Western blotting and immunofluorescence, followed by GEF-H1 knockdown. Immunofluorescence and renal histology were used to examine the cysts, inflammation, and fibrosis. A RhoA GTPase activation assay and Western blotting were used to detect the expression of downstream GTP-RhoA and p-MLC2, respectively. In NPHP1 knockdown (NPHP1KD) human kidney proximal tubular cells (HK2 cells), we detected the expressions of E-cadherin and α-smooth muscle actin (α-SMA). In vivo, increased expression and redistribution of GEF-H1, and higher levels of GTP-RhoA and p-MLC2 in renal tissue of NPHP1KO mice were observed, together with renal cysts, fibrosis, and inflammation. These changes were alleviated by GEF-H1 knockdown. In vitro, the expression of GEF-H1 and activation of RhoA were also increased, with increased expression of α-SMA and decreased E-cadherin. GEF-H1 knockdown reversed these changes in NPHP1KD HK2 cells. Thus, the GEF-H1/RhoA/MLC2 axis is activated in NPHP1 defects and may play a pivotal role in NPHP pathogenesis.
- 20 August 2021
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 31 (2) , 232-243
An Nphp1 knockout mouse model targeting exon 2–20 demonstrates characteristic phenotypes of human nephronophthisis
Nephronophthisis (NPH) is the most prevalent monogenetic disorder leading to end-stage renal failure (ESRD) in childhood. Mutations in Nphp1, encoding a cilia-localized protein, account for the majority of NPH cases. Despite its identification many years ago, Nphp1 deletions targeting exon 4 or exon 20 have not reproduced the histological features of human NPH in murine models. In this study, we deleted exon 2–20 of Nphp1 by CRISPR/Cas9 gene editing to create a near-total knockout (KO) mouse model (Nphp1del2–20/del2–20). Nphp1del2–20/del2–20 mice faithfully reproduced the renal and extrarenal phenotypes associated with human NPH, including renal cyst development, tubular basement membrane thickening, retinal degeneration and abnormal spermatogenesis. Importantly, Nphp1 re-expression using an adenoviral-associated-virus-9 vector could partially rescue both renal and retinal phenotypes in Nphp1del2–20/del2–20 mice. Our results reported the first relevant Nphp1 mouse model with renal phenotypes for human disease. It will be a valuable model for future studies of Nphp1 function and to develop novel treatments for this common childhood disease.
- 20 August 2021
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 31 (2) , 232-243
An Nphp1 knockout mouse model targeting exon 2–20 demonstrates characteristic phenotypes of human nephronophthisis
Nephronophthisis (NPH) is the most prevalent monogenetic disorder leading to end-stage renal failure (ESRD) in childhood. Mutations in Nphp1, encoding a cilia-localized protein, account for the majority of NPH cases. Despite its identification many years ago, Nphp1 deletions targeting exon 4 or exon 20 have not reproduced the histological features of human NPH in murine models. In this study, we deleted exon 2–20 of Nphp1 by CRISPR/Cas9 gene editing to create a near-total knockout (KO) mouse model (Nphp1del2–20/del2–20). Nphp1del2–20/del2–20 mice faithfully reproduced the renal and extrarenal phenotypes associated with human NPH, including renal cyst development, tubular basement membrane thickening, retinal degeneration and abnormal spermatogenesis. Importantly, Nphp1 re-expression using an adenoviral-associated-virus-9 vector could partially rescue both renal and retinal phenotypes in Nphp1del2–20/del2–20 mice. Our results reported the first relevant Nphp1 mouse model with renal phenotypes for human disease. It will be a valuable model for future studies of Nphp1 function and to develop novel treatments for this common childhood disease.